Focused On-demand Library for Transcription initiation factor TFIID subunit 13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q15543

UPID:

TAF13_HUMAN

Alternative names:

Transcription initiation factor TFIID 18 kDa subunit

Alternative UPACC:

Q15543; B2R5E5; Q5TYV6

Background:

Transcription initiation factor TFIID subunit 13, also known as the 18 kDa subunit, is integral to the TFIID basal transcription factor complex, crucial for the initiation of RNA polymerase II-dependent transcription. This complex, comprising TBP and various TAFs, is pivotal in promoter recognition, binding, and pre-initiation complex assembly. TAF13, alongside TAF11 and TBP, plays a significant role in promoter binding by TFIID and TFIIA transcription factor complexes.

Therapeutic significance:

Intellectual developmental disorder, autosomal recessive 60, characterized by mild intellectual disability and delayed psychomotor development, is linked to variants affecting the gene encoding TFIID subunit 13. Understanding the role of Transcription initiation factor TFIID subunit 13 could open doors to potential therapeutic strategies for this disorder.